VERVE THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
VERVE THERAPEUTICS INC. - More news...
VERVE THERAPEUTICS INC. - More news...
- Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
- Verve Therapeutics Receives U.S. FDA Fast Track Designation for VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
- Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones
- Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial Results
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Leadership Update
- Verve Therapeutics to Participate in Upcoming Investor Conferences
- Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
- Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Updates on its PCSK9 Program
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
